期刊文献+

93例转移性恶性黑色素瘤预后分析 被引量:6

Prognostic Factors in Patients with Metastatic Malignant Melanoma
下载PDF
导出
摘要 目的:探讨转移性恶性黑色素瘤的预后因素。方法:回顾性分析93例经病理证实的转移性恶性黑色素瘤患者的临床资料及实验室、影像学检查结果。结果:93例转移性恶性黑色素瘤患者2年生存率为10.8%(10/93)。性别、体质状况、有无肝脏转移、转移部位数目、血清LDH水平、白蛋白水平以及转移灶是否切除对患者的2年生存率有显著影响;而不同年龄患者的2年生存率无统计学差异。结论:女性、体质状况较好、无肝脏转移、单一部位转移、LDH或白蛋白水平正常以及孤立转移病灶的手术切除是预后好的指标。 Objective: To determine clinical prognostic factors that accurately predict survival in patients with metastatic melanoma. Methods: 93 patients with metastatic malignant melanoma were analysed retrospectively. Results: 10.8% of all patients with distant metastasis of melanoma lived for more than 2 years. There was significant difference in 2-year survival rate between men and women,KPS≥80 and <80, liver and without liver involvement,one and multiple organ involvements, normal and elevated serum level of LDH, normal and decreased serum albumin, respectively. There was no difference between≥50 years and <50 years. Conclusion: Female, good performance status, without liver involvement, single organ metastase, normal LDH and albumin level, resection of the isolated focus are highly significant predictors of good survial.
作者 李曙光 黎莉
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2004年第8期446-448,共3页 Chinese Journal of Clinical Oncology
关键词 恶性黑色素瘤 预后因素 生存 Melanoma Prognostic factors Survival
  • 相关文献

参考文献11

  • 1[1]Barth A, Wanek LA, Morton DL. Prognostic factors in 1521melanoma patients with distant metastases [J]. J Am Coil Surg,1995, 181(2):193~201
  • 2[2]Manola J,Atkins M.Ibrahim J,et al. Prognostic factors in metastatic melanoma:a pooled analysis of Eastern Cooperative Oncology Group Trials[J].J Clin Oncol, 2000, 18(22):3782~3793
  • 3[3]Joseph MU, Lawrence EF, Liu PY, et al. Gender and other survival predictors in patients with metastatic melanoma on southwest oncology[J]. Cancer, 2001, 91 (6):1148~1155
  • 4[4]Louise R, Andrew K, Ernest B. Prognostic factors in metastatic melanoma[J]. Cancer, 1993, 71(10):2995~3005
  • 5[5]Matthew NS, Dean FB, George YC, et al. Prognostic factors in patients with metastatic malignant melanoma[J]. Cancer, 1993, 72(10):3091~3097
  • 6[6]Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population [J]. Ann Surg Oncol,1994,1 (6):487~494
  • 7[7]McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer [J]. Nutr Cancer,2001, 41(1~2):64~69
  • 8[8]Fletcher WS, Pommier RF, Lum S, et al. Surgical treatment of metastatic melanoma[J]. AmJ Surg, 1998,175(5):413~417
  • 9[9]Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma[J]. Cancer, 2000, 89(9):1983~1991
  • 10[10]Hoffmann R, Muller I, Neuber K, et al. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin,BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a [J]. BrJ Cancer, 1998, 78(8):1076~1080

同被引文献35

  • 1叶明福,张哉根,王亚丽,汤金梁.恶性黑色素瘤组织学变异型与鉴别诊断[J].临床与实验病理学杂志,2004,20(5):588-591. 被引量:39
  • 2Schade VL, Roukis TS, Homann JF, et al. "The malignant wart": a review of primary nodular melanoma of the foot and report of two cases[J]. J Foot Ankle Surg, 2010, 49(3): 263-273.
  • 3Bristow IR, Acland K. Acral lentiginous melanoma of the foot and ankle: a case series and review of the literature[J]. J Foot Ankle Res, 2008, 1(1): 11.
  • 4Dwyer PK, Mackie RM, Watt DC, et al. Plantar malignant melanoma in a white Caucasian population[J]. Br J Dermatol, 1993, 128(2): 115-120.
  • 5Fortin PT, Freiberg AA, Rees R, et al. Malignant melanoma of the foot and ankle[J]. J Bone Joint Surg Am, 1995, 77(9): 1396-1403.
  • 6Metzger S, Ellwanger U, Stroebel W, et al. Extent and consequences of physician delay in the diagnosis of acral melanoma[J]. Melanoma Res, 1998, 8(2): 181-186.
  • 7Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new- onset diabetic foot ulcers stratified by etiology[J]. Diabetes Care, 2003, 26(2):491-494.
  • 8Lens MB, Dawes M. Global perspectives of contemporary epidemiologieal trends of cutaneous malignant melanoma[J]. Br J Dermatol, 2004, 150(2): 179-185.
  • 9Albreski D, Sloan SB. Melanoma of the feet: misdiagnosed and misunderstood[J]. Clin Dermatol, 2009, 27(6): 556-563.
  • 10Gualandri L, Betti R, Crosti C, et al. Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay[J]. J Eur Acad Dermatol Venereol, 2009, 23(3): 283-287.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部